Verdict: Side-by-side breakdown using the Bull Rankings model. EXR scored 69.0, PSA scored 73.0 — PSA leads.
Compare another set
Different reporting periods. PSA's fundamentals are as of June 2026, but EXR's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
EXR
Extra Space Storage Inc.
REIT - Industrial · Financial strength
68.3Fin
$134.65 · $29.7B
fundamentals as of
Strength gap
10.6
EXR leads
PSA
Public Storage
REIT - Industrial · Financial strength
57.7Fin
$289.86 · $54.2B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
Fastest growthEXR+3.7%
Strongest balance sheetEXR1.02
Side by side · every name on one set of axes
Fundamentals, head-to-head
EXR
PSA
4.9%B+
Yield
4.2%B+
+3.7%C+
Rev
+2.7%C
1.02B
D/E
1.10B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
EXRExtra Space Storage Inc.
REIT - Industrial · $134.65 · beta 1.17
Why now
REIT - Industrial · market cap $29.7b. 15% off the 52-week high of $158.88. 20 sell-side analysts rate this a Buy with a mean 1-yr target of $158.25 (implying +18% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close.
Risk
Dividend payout 143% of earnings on a 4.9% yield — distribution coverage is thin; one earnings stumble could force a dividend cut. ROE 7% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
PSAPublic Storage
REIT - Industrial · $289.86 · beta 0.93
Why now
REIT - Industrial · market cap $54.2b. 14% off the 52-week high of $335.55. 18 sell-side analysts rate this a Buy with a mean 1-yr target of $335.06 (implying +16% upside).
Moat
Net margin 42% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 22% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. $54.2b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Dividend payout 115% of earnings on a 4.2% yield — distribution coverage is thin; one earnings stumble could force a dividend cut. P/S 11.0x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Common questions
Is PSA or EXR the better stock?
PSA scores higher: PSA 73.0, EXR 69.0 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
How are PSA and EXR scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.